Dedifferentiated liposarcoma of the extremities: a Korean multi-center study of 107 cases.
Dedifferentiated liposarcoma
Disease specific survival
Extremities
Local recurrence
Metastasis
Multi-center
Oncologic outcome
Soft tissue sarcoma
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
received:
27
06
2024
accepted:
01
10
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
10
10
2024
Statut:
epublish
Résumé
Dedifferentiated liposarcoma of the extremities (DDL-E) is rare in comparison to that of the retroperitoneum. Its clinical features and surgical principle for resection margins at the dedifferentiated and the well-differentiated components are yet to be elucidated. This retrospective multi-center study examined patients diagnosed with DDL-E from August 2004 to May 2023 at 5 sarcoma centers. Clinical features, oncologic outcomes, and prognostic factors were analyzed. A total of 107 patients were reviewed. The 5-year local recurrence free survival (LRFS), metastasis-free survival (MFS) and disease specific survival (DSS) were 84.7%, 78.6%, and 87.8%, respectively. Other primary malignancies and extrapulmonary metastasis were observed in 27 and 4 patients, respectively. The independent risk factor for local recurrence was R1/2 margin at the dedifferentiated component of the tumor. Metastasis was associated with tumor size in univariate analysis. The independent risk factor for DSS was tumor grade. Previous unplanned excision, de novo presentation, tumor depth, absence of the well-differentiated component, infiltrative border, R1/2 margin at the well-differentiated component were not associated with oncologic outcomes. This is the largest study examining DDL-E to-date. Localized DDL-E has low potential for metastasis and carries an excellent prognosis. Other primary malignancy and extrapulmonary metastasis are more frequent in DDL-E, thus close monitoring of other sites during follow-up is recommended. While wide resection margin is the standard surgical approach for DDL-E, further investigation into moderated wide resection margin at the well-differentiated component is warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Dedifferentiated liposarcoma of the extremities (DDL-E) is rare in comparison to that of the retroperitoneum. Its clinical features and surgical principle for resection margins at the dedifferentiated and the well-differentiated components are yet to be elucidated.
METHODS
METHODS
This retrospective multi-center study examined patients diagnosed with DDL-E from August 2004 to May 2023 at 5 sarcoma centers. Clinical features, oncologic outcomes, and prognostic factors were analyzed.
RESULTS
RESULTS
A total of 107 patients were reviewed. The 5-year local recurrence free survival (LRFS), metastasis-free survival (MFS) and disease specific survival (DSS) were 84.7%, 78.6%, and 87.8%, respectively. Other primary malignancies and extrapulmonary metastasis were observed in 27 and 4 patients, respectively. The independent risk factor for local recurrence was R1/2 margin at the dedifferentiated component of the tumor. Metastasis was associated with tumor size in univariate analysis. The independent risk factor for DSS was tumor grade. Previous unplanned excision, de novo presentation, tumor depth, absence of the well-differentiated component, infiltrative border, R1/2 margin at the well-differentiated component were not associated with oncologic outcomes.
CONCLUSIONS
CONCLUSIONS
This is the largest study examining DDL-E to-date. Localized DDL-E has low potential for metastasis and carries an excellent prognosis. Other primary malignancy and extrapulmonary metastasis are more frequent in DDL-E, thus close monitoring of other sites during follow-up is recommended. While wide resection margin is the standard surgical approach for DDL-E, further investigation into moderated wide resection margin at the well-differentiated component is warranted.
Identifiants
pubmed: 39390540
doi: 10.1186/s12885-024-13021-y
pii: 10.1186/s12885-024-13021-y
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1259Informations de copyright
© 2024. The Author(s).
Références
Evans HL, Khurana KK, Kemp BL, Ayala AG. Heterologous elements in the dedifferentiated component of dedifferentiated liposarcoma. Am J Surg Pathol. 1994;18(11):1150.
doi: 10.1097/00000478-199411000-00009
pubmed: 7943536
Henricks WH, Chu YC, Goldblum JR, Weiss SW. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol. 1997;31(3):271.
doi: 10.1097/00000478-199703000-00002
Le Guellec S, Chibon F, Ouali M, et al. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas? Am J Surg Pathol. 2014;38(3):293–304. https://doi.org/10.1097/PAS.0000000000000131 .
doi: 10.1097/PAS.0000000000000131
pubmed: 24525499
Sbaraglia M, Bellan E, Dei Tos A. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives - PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167394/ . Accessed 1 Aug 2023.
Kransdorf MJ, Meis JM, Jelinek JS. Dedifferentiated liposarcoma of the extremities: imaging findings in four patients. Am J Roentgenol. 1993;161(1):127–30. https://doi.org/10.2214/ajr.161.1.8517290 .
doi: 10.2214/ajr.161.1.8517290
McCormick D, Mentzel T, Beham A, Fletcher CD. Dedifferentiated liposarcoma. Clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. AM J Surg Pathol. 1994;18(12):1213–23. https://doi.org/10.1097/00000478-199412000-00004 .
doi: 10.1097/00000478-199412000-00004
pubmed: 7977944
Hoshi M, Matsumoto S, Manabe J, et al. Surgery for dedifferentiated liposarcoma, presenting two radiologically and pathologically distinctive patterns. Jpn J Clin Oncol. 2006;36(7):462–7. https://doi.org/10.1093/jjco/hyl073 .
doi: 10.1093/jjco/hyl073
pubmed: 16887838
Okada K, Hasegawa T, Kawai A, et al. Primary (De Novo) dedifferentiated liposarcoma in the extremities: a multi-institution Tohoku musculoskeletal tumor society study of 18 cases in Northern Japan. Jpn J Clin Oncol. 2011;41(9):1094–100. https://doi.org/10.1093/jjco/hyr098 .
doi: 10.1093/jjco/hyr098
pubmed: 21795247
Kito M, Yoshimura Y, Isobe K, et al. Clinical outcome of dedifferentiated liposarcoma in the extremities: A retrospective case series of 7 patients. J Orthop Sci. 2016;21(5):673–7. https://doi.org/10.1016/j.jos.2016.05.006 .
doi: 10.1016/j.jos.2016.05.006
pubmed: 27317086
Nakata E, Kunisada T, Hasei J, et al. What Are the results of resection of localized dedifferentiated liposarcomas in the extremities? Clin Orthop Relat Res. 2020;478(11):2550. https://doi.org/10.1097/CORR.0000000000001338 .
doi: 10.1097/CORR.0000000000001338
pubmed: 33112583
pmcid: 7594912
Tseng WW, Barretta F, Baia M, et al. Dedifferentiation within well-differentiated liposarcoma of the extremity or trunk: Implications for clinical management. J Surg Oncol. 2021;124(5):838–45. https://doi.org/10.1002/jso.26590 .
doi: 10.1002/jso.26590
pubmed: 34254688
Morii T, Anazawa U, Sato C, et al. Dedifferentiated liposarcoma in the extremity and trunk wall: A multi-institutional study of 132 cases by the Japanese Musculoskeletal Oncology Group (JMOG). Eur J Surg Oncol. 2023;49(2):353–61. https://doi.org/10.1016/j.ejso.2022.08.024 .
doi: 10.1016/j.ejso.2022.08.024
pubmed: 36088237
Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350–62. https://doi.org/10.1200/JCO.1997.15.1.350 .
doi: 10.1200/JCO.1997.15.1.350
pubmed: 8996162
Jour G, Gullet A, Liu M, Hoch BL. Prognostic relevance of Fédération Nationale des Centres de Lutte Contre le Cancer grade and MDM2 amplification levels in dedifferentiated liposarcoma: a study of 50 cases. Mod Pathol. 2015Jan 1;28(1):37–47.
doi: 10.1038/modpathol.2014.88
pubmed: 25059573
Wittekind C, Compton C, Quirke P, et al. A uniform residual tumor (R) classification. Cancer. 2009;115(15):3483–8. https://doi.org/10.1002/cncr.24320 .
doi: 10.1002/cncr.24320
pubmed: 19536900
Fluss R, Faraggi D, Reiser B. Estimation of the Youden index and its associated cutoff point. Biom J. 2005;47(4):458–72. https://doi.org/10.1002/bimj.200410135 .
doi: 10.1002/bimj.200410135
pubmed: 16161804
Bartlett EK, Curtin CE, Seier K, et al. Histologic subtype defines the risk and kinetics of recurrence and death for primary extremity/truncal liposarcoma. Ann Surg. 2021;273(6):1189–96. https://doi.org/10.1097/SLA.0000000000003453 .
doi: 10.1097/SLA.0000000000003453
pubmed: 31283560
Thway K. Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review. Semin Diagn Pathol. 2019;36(2):112–21. https://doi.org/10.1053/j.semdp.2019.02.006 .
doi: 10.1053/j.semdp.2019.02.006
pubmed: 30852045
Keung EZ, Hornick JL, Bertagnolli MM, Baldini EH, Raut CP. Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery. J Am Coll Surg. 2014;218(2):206–17. https://doi.org/10.1016/j.jamcollsurg.2013.10.009 .
doi: 10.1016/j.jamcollsurg.2013.10.009
pubmed: 24315890
Dei Tos AP. Liposarcomas: diagnostic pitfalls and new insights. Histopathology. 2014;64(1):38–52. https://doi.org/10.1111/his.12311 .
doi: 10.1111/his.12311
pubmed: 24118009
Jung E, Fiore M, Gronchi A, et al. Second primary malignancies in patients with well-differentiated/dedifferentiated liposarcoma. Anticancer Res. 2018;38(6):3535–42. https://doi.org/10.21873/anticanres.12625 .
doi: 10.21873/anticanres.12625
pubmed: 29848707
pmcid: 7492098
Vogt A, Schmid S, Heinimann K, et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017;2(2): e000172. https://doi.org/10.1136/esmoopen-2017-000172 .
doi: 10.1136/esmoopen-2017-000172
pubmed: 28761745
pmcid: 5519797
Al-Absi E, Farrokhyar F, Sharma R, et al. A systematic review and meta-analysis of oncologic outcomes of pre- versus postoperative radiation in localized resectable soft-tissue sarcoma. Ann Surg Oncol. 2010;17(5):1367–74. https://doi.org/10.1245/s10434-009-0885-7 .
doi: 10.1245/s10434-009-0885-7
pubmed: 20217260
Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003;21(14):2719–25. https://doi.org/10.1200/JCO.2003.02.026 .
doi: 10.1200/JCO.2003.02.026
pubmed: 12860950
Haas RLM, Bonvalot S, Miceli R, et al. Radiotherapy for retroperitoneal liposarcoma: A report from the transatlantic retroperitoneal sarcoma working group. Cancer. 2019;125(8):1290–300. https://doi.org/10.1002/cncr.31927 .
doi: 10.1002/cncr.31927
pubmed: 30602058
Hasegawa T, Yamamoto S, Yokoyama R, Umeda T, Matsuno Y, Hirohashi S. Prognostic significance of grading and staging systems using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer. 2002;95(4):843–51. https://doi.org/10.1002/cncr.10728 .
doi: 10.1002/cncr.10728
pubmed: 12209729